Anticoagulation and Antiplatelet Therapy — DCE Clinical Case

Focused history — what you must establish

• The clot: symptom onset, exertional tolerance, haemoptysis, syncope — and any prior VTE or family history that reframes "unprovoked" [4].
• The provoking-factor hunt: recent surgery, immobilisation, long-haul travel, oestrogen therapy — their absence is what makes this unprovoked and triggers the malignancy lens [4].
• The cancer screen: weight loss, change in bowel habit, rectal bleeding, haemoptysis, night sweats, new lumps, dysphagia, urinary symptoms; screening participation (bowel, prostate); smoking and alcohol history.
• Bleeding-risk inventory: prior GI bleeding, NSAID use, antiplatelets, liver disease, renal function — these will shape agent choice once the caecal mass is confirmed, because an unresected GI luminal tumour changes the bleeding calculus [1] [2].
• The treatment horizon: planned colonoscopy (biopsy bleeding), likely surgery, and probable chemotherapy with its interactions and thrombocytopenia — the anticoagulant must survive his cancer journey.
• The patient's frame: what he has been told, what he fears, and his capacity for twice-daily tablets versus injections.

Examination priorities

Haemodynamics and oxygenation; leg examination for a residual DVT source; abdominal examination for masses and hepatomegaly; rectal examination; lymphadenopathy including supraclavicular nodes; chest signs; signs of chronic liver disease; baseline weight and performance status — the examination is simultaneously VTE assessment and occult-malignancy screen [4].

Presentation template (deliver this to the examiner)

"Mr Antoniou is a 61-year-old man with a first unprovoked segmental pulmonary embolism, haemodynamically stable, on a background of 6 kg weight loss and a change in bowel habit, with a caecal mass now demonstrated. This is cancer-associated VTE until histology proves otherwise. My anticoagulation plan must treat the clot safely today, survive biopsy, surgery and likely chemotherapy, and run for as long as his cancer is active — and I will choose the agent against his specific bleeding anatomy: a luminal colonic primary." [1] [3]

Management — what you will actually do

1. Anticoagulate now. Stable cancer-associated VTE gets a DOAC as the default: apixaban 10 mg twice daily for 7 days then 5 mg twice daily is the cleanest evidence base — Caravaggio showed non-inferior recurrence prevention versus dalteparin with no increase in major bleeding [1].
2. Apply the GI-tumour caveat honestly. Edoxaban in Hokusai VTE Cancer showed non-inferiority on the recurrence/bleeding composite but MORE major bleeding in GI cancers — so with an unresected caecal primary I either choose apixaban on its cleaner profile or use LMWH until the tumour is resected, and I say that reasoning aloud rather than prescribing by class reflex [1] [2].
3. Complete the occult-malignancy workup proportionately. The response to unprovoked VTE is targeted — history, examination, FBC, chemistry, calcium, urinalysis, chest imaging, and age-appropriate screening — not reflex total-body scanning; here the history already pointed the way, and colonoscopy with biopsy is the diagnostic step [4].
4. Plan the procedural interruptions. Colonoscopic biopsy of a vascular tumour: brief DOAC interruption (24–48 hours by bleeding risk), no bridging; cancer surgery (likely hemicolectomy): hold per high-bleed-risk protocol, resume at 48–72 hours when haemostasis allows, with prophylactic dosing in between [3].
5. Set duration as a standing decision. Minimum 6 months, continuing while the cancer is active or he is on active treatment, reassessed periodically; if he achieves durable remission, revisit stopping at that point; if extended therapy continues beyond the initial phase, reduced-dose apixaban (2.5 mg bd) has evidence for extended protection after the first 6 months from AMPLIFY-EXT [3] [5].
6. Integrate with oncology early. Chemotherapy interactions (P-gp/CYP3A4 paths), anticipated thrombocytopenia (half-dose or hold strategies below about 50 × 10⁹/L), vomiting and malabsorption (a reason to prefer LMWH transiently), and central-line-associated thrombosis surveillance all belong in the shared plan [3].

Probing questions

"Why did you reach for a DOAC rather than the traditional dalteparin?" — "The evidence moved. Caravaggio gave apixaban non-inferior recurrence prevention with no bleeding penalty against dalteparin, and Hokusai showed edoxaban non-inferior on the composite — so oral therapy is the default for most patients, sparing him months of daily injections. I retain LMWH for the situations the trials flagged: unresected GI luminal bleeding risk, heavy chemotherapy interactions, thrombocytopenia, or absorption concerns — and I am watching his caecal mass against exactly that list" [1] [2].

"Does the unprovoked PE itself change his cancer management?" — "Three ways: it is a marker of more aggressive tumour biology and needs documenting in the oncology handover; it constrains surgery timing and mandates perioperative anticoagulation planning rather than interruption by default; and thromboprophylaxis thinking extends to any future admissions and to central lines" [3].

"When would you stop anticoagulation?" — "Not at 6 months by the calendar — at 6 months I reassess. Continuing active cancer or active treatment means continuing anticoagulation. Durable remission, a rising bleeding risk, or his informed preference after honest numbers are the legitimate exits, and each review is documented as a fresh decision" [3] [5].

"His platelets fall to 45 on chemotherapy. Walk me through it." — "Below about 50 × 10⁹/L full-dose anticoagulation becomes hazardous: I would move to half-dose LMWH or DOAC by protocol, hold entirely only if the count collapses further or he bleeds, transfuse platelets only for bleeding or procedural thresholds, and restart full intensity as the count recovers — the clot risk does not pause for his nadir" [3].